JP2026041756A5 - - Google Patents

Info

Publication number
JP2026041756A5
JP2026041756A5 JP2025193397A JP2025193397A JP2026041756A5 JP 2026041756 A5 JP2026041756 A5 JP 2026041756A5 JP 2025193397 A JP2025193397 A JP 2025193397A JP 2025193397 A JP2025193397 A JP 2025193397A JP 2026041756 A5 JP2026041756 A5 JP 2026041756A5
Authority
JP
Japan
Prior art keywords
antibody
chain
hcdr
region
lcdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025193397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026041756A (ja
Filing date
Publication date
Priority claimed from JP2022545429A external-priority patent/JP7815595B2/ja
Application filed filed Critical
Publication of JP2026041756A publication Critical patent/JP2026041756A/ja
Publication of JP2026041756A5 publication Critical patent/JP2026041756A5/ja
Pending legal-status Critical Current

Links

JP2025193397A 2020-01-29 2025-11-13 抗mdr1抗体およびその使用 Pending JP2026041756A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062967470P 2020-01-29 2020-01-29
US62/967,470 2020-01-29
US202063085818P 2020-09-30 2020-09-30
US63/085,818 2020-09-30
JP2022545429A JP7815595B2 (ja) 2020-01-29 2021-01-28 抗mdr1抗体およびその使用
PCT/US2021/015534 WO2021155028A1 (en) 2020-01-29 2021-01-28 Anti-mdr1 antibodies and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022545429A Division JP7815595B2 (ja) 2020-01-29 2021-01-28 抗mdr1抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2026041756A JP2026041756A (ja) 2026-03-10
JP2026041756A5 true JP2026041756A5 (enExample) 2026-05-14

Family

ID=74673398

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022545429A Active JP7815595B2 (ja) 2020-01-29 2021-01-28 抗mdr1抗体およびその使用
JP2025193397A Pending JP2026041756A (ja) 2020-01-29 2025-11-13 抗mdr1抗体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022545429A Active JP7815595B2 (ja) 2020-01-29 2021-01-28 抗mdr1抗体およびその使用

Country Status (10)

Country Link
US (1) US20230203156A1 (enExample)
EP (1) EP4097134A1 (enExample)
JP (2) JP7815595B2 (enExample)
KR (1) KR20220133884A (enExample)
CN (1) CN115023443A (enExample)
AU (1) AU2021214370A1 (enExample)
BR (1) BR112022013870A2 (enExample)
CA (1) CA3164608A1 (enExample)
MX (1) MX2022009355A (enExample)
WO (1) WO2021155028A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
KR20240116829A (ko) * 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
CN120957755A (zh) * 2023-05-12 2025-11-14 四川科伦博泰生物医药股份有限公司 多环类药物偶联物及其制备方法和用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025232118A1 (zh) * 2024-05-10 2025-11-13 四川科伦博泰生物医药股份有限公司 稠环类化合物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌/抗ウイルス性化合物原料としてのイチイ培養組織
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5821263A (en) 1996-08-26 1998-10-13 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
SK182599A3 (en) 1997-06-20 2000-07-11 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
JP4153660B2 (ja) 1997-10-08 2008-09-24 株式会社横浜国際バイオ研究所 タキソイド誘導体およびその製造方法
WO2006108070A2 (en) * 2005-04-06 2006-10-12 Cedars-Sinai Medical Center Inhibition of p-glycoprotein using act modulators and uic2 monoclonal antibody
CN110655582B (zh) * 2015-01-08 2022-12-16 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物
WO2018099539A1 (en) * 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
EP3700938A1 (en) * 2017-10-26 2020-09-02 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. Novel recombinant fusion proteins, preparation and use thereof
BR112021019701A2 (pt) * 2019-04-02 2021-12-14 Kenjockety Biotechnology Inc Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos

Similar Documents

Publication Publication Date Title
CN112574307B (zh) 抗人Claudin18.2抗体及其应用
CN115551888B (zh) 抗cd73抗体及其用途
JP2024522360A5 (enExample)
CN112135626A (zh) 抗tigit抗体及其用途
JP2021524478A5 (enExample)
RU2018124602A (ru) Новые анти-pd-l1 антитела
JP2024506315A5 (enExample)
JP2022533538A5 (enExample)
RU2012112829A (ru) Анти-gitr-антитела
JP2023540526A5 (enExample)
JP2022527860A5 (enExample)
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2022539589A5 (enExample)
JP2023528416A5 (enExample)
CN115785268B (zh) 抗cd47抗体及其用途
JP2025505650A5 (enExample)
JP7653532B2 (ja) 抗Siglec15抗体およびその使用
JP2025508317A5 (enExample)
KR20250152073A (ko) 항체, 항원 결합 단편 및 사용 방법
JP2022547718A5 (enExample)
CN119176874A (zh) 一种能够结合lilrb2的抗体或其抗原结合片段
JP2025513714A5 (enExample)
CN119285774A (zh) 抗人tigit单克隆抗体tigit-m007或其功能性片段及其应用
JP2021533806A5 (enExample)
JP2022505144A5 (enExample)